Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PrecigenPGEN +5.38%55 Median PS Value is $1.25 as of Aug. 01, 2026, which is 74% below its 10-year median of 4.83. GuruFocus rates PGEN with a GF Score™ of 55/100 and a GF Value™ of $6.05 (Fairly Valued). The stock has 10 warning signs investors should review. Among 276 Biotechnology companies, Precigen ranks worse than 94.2% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Precigen's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.092. Precigen's 10-Year median PS Ratio is 13.587. Therefore, the Median PS Value for today is $1.25.
As of today (2026-08-01), Precigen's share price is $6.27. Precigen's Median PS Value is $1.25. Therefore, Precigen's Price to Median PS Value for today is 5.02.
The historical rank and industry rank for Precigen's Median PS Value or its related term are showing as below:
PGEN'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.73 Med: 4.83 Max: 10.97
Current: 5.02
During the past 13 years, the highest Price to Median PS Value of Precigen was 10.97. The lowest was 0.73. And the median was 4.83.
PGEN's Price-to-Median-PS-Value is ranked worse than 94.2% of 276
companies
in the Biotechnology industry
Industry Median: 0.615
vs PGEN: 5.02
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Precigen's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
6.27
/
1.25
=
5.02
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Precigen Median PS Value Related Terms
Precigen Median PS Value Historical Data
* Premium members only.
The historical data trend for Precigen's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PGEN vs GLUE, ZBIO, ADMA: Median PS Value Comparison
For the Biotechnology subindustry, Precigen's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Precigen Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Precigen's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Precigen's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 13.587.
Precigen's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.092.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Precigen (PGEN) has a Median PS Value of $1.25 as of Aug. 01, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Precigen and its competitors. This is 74% below median its historical median of 4.83. Over the past decade, Precigen's Median PS Value has ranged from 0.73 to 10.97. According to the industry distribution chart, Precigen ranks #260 out of 276 companies in the Biotechnology industry, placing it in the top 94.2%.
Is Precigen's Median PS Value too high?
Precigen's current Median PS Value of $1.25 is 74% below median its 10-year median of 4.83. Over the past 10 years, this metric has ranged from a low of 0.73 to a high of 10.97. The Biotechnology industry median Median PS Value is 0.62. Precigen's value of $1.25 is 103.3% above this industry median. Based on the distribution chart, Precigen ranks #260 out of 276 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Precigen has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Precigen's Median PS Value compare to GLUE and ZBIO?
According to the Biotechnology industry distribution chart, Precigen ranks #260 out of 276 companies for Median PS Value. This places Precigen in the lower half of its industry. The industry median Median PS Value is 0.62. Precigen's value of $1.25 is 103.3% above this benchmark. Historically, Precigen's own Median PS Value has ranged from 0.73 to 10.97 over the past decade. While the company's 10-year median is 4.83 vs. the industry median of 0.62, Precigen has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.62, based on 276 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Precigen's current Median PS Value of $1.25 is 103.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Precigen and its competitors. For the Biotechnology industry, the median Median PS Value is 0.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Precigen's current Median PS Value is $1.25, which is 74% below median its own 10-year median of 4.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Precigen stock overvalued right now?
Based on GuruFocus' analysis, Precigen (PGEN) is currently considered Fairly Valued. The stock's GF Value™ is $6.05, compared to a current price of $6.27 — trading 3.6% above its estimated fair value. The current Median PS Value is $1.25, which is 74% below median its 10-year median of 4.83 and 103.3% above the Biotechnology industry median of 0.62. Precigen's overall GF Score™ is 55/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Precigen (PGEN), the current Median PS Value is $1.25 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Precigen (PGEN) Overvalued in 2026?
Based on GuruFocus' analysis, Precigen stock appears to be overvalued.
The current stock price of $6.27 is trading 3.6% above its estimated GF Value™ of $6.05.
GuruFocus considers Precigen to be Fairly Valued.
Key valuation signals for PGEN:
Median PS Value: $1.25 (74% below median its 10-year median of 4.83)
GF Value™: $6.05 vs. price of $6.27 (3.6% above fair value)
Industry Position: 103.3% above the Biotechnology median (#260 of 276)
No single metric tells the full story. See the PGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
55GF Score
Get the complete analysis for PGEN
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PGEN has been successfully added to your 
